The farnesoid X receptor (FXR) is a nuclear receptor superfamily member and ligand-activated transcription factor. By binding to DNA as a monomer or a heterodimer with the common NR partner, retinoid x receptor (RXR), to FXR response elements, FXR controls the expression of numerous genes. The FXR and FXR genes are the two recognized FXR genes.
FXR is primarily expressed in the liver and small intestine, where it is critical for the metabolism of bile acids, lipids, and glucose. FXR regulates bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, as well as playing a significant role in intestinal bacterial growth and liver regeneration through its specific target genes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79540 | FXRagonist 4 | FXR agonist 4 (compound 10a) is a farnesoid X receptor (FXR) agonist/activator with EC50 of 1.05 μM. | |
|
V74031 | FXRagonist 5 | 2414008-05-0 | FXR agonist 5 (compound 1) is an FXR agonist. |
|
V29731 | Gly-β-MCA | 66225-78-3 | Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be usedfor the treatment of metabolic disorders. |
|
V79622 | Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5) | Glyco-Obeticholic acid-d5 is the deuterated form of Glyco-Obeticholic acid. | |
|
V74024 | HEC96719 | 2181834-03-5 | HEC96719 is a selective and orally bioactive tricyclic farnesoid X receptor (FXR) agonist/activator with EC50s of 1.37 and 1.55 nM via time-resolved fluorescence energy transfer (TR-FRET) and luciferase, respectively. |
|
V74030 | Hedragonic acid | 466-02-4 | Hedragonic acid is an oleanane-type triterpenoid that can be extracted from the stems and roots of Hedragonic acid. |
|
V104784 | HPG1860 | 2226133-29-3 | HPG1860 is an orally active, highly selective and potent FXR agonist with EC50 of 18 nM (FXR-luciferase reporter assay). |
|
V93766 | Lecufexor | 2247972-61-6 | Lecufexor is a farnesoid X receptor (FXR) agonist. |
|
V104304 | LH10 | LH10 is a fexaramine-based FXR agonist with an EC50 of 0.14 μM. | |
|
V87446 | Linafexor | 2765593-43-7 | inafexor (CS-0159) is an agonist of the farnesoid X receptor (FXR). |
|
V104460 | LZ-007 | 2920000-23-1 | LZ-007 LZ-007 is an agonist of farnesoid X receptor (FXR) with EC50 of 51 nM as determined by TR-FRET and EC50 of 76 nM for FXR in HepG2 cells. |
|
V74027 | Nelumol A | 77836-86-3 | Nelumol A is a farnesoid X receptor (FXR) agonist. |
|
V87445 | PX20606 | 1268245-19-7 | PX20606 is an orally available farnesoid X receptor (FXR) agonist with EC50 of 220 nM (mFXR) and 50 nM (hFXR) as determined by Gal4-FXR. |
|
V103104 | Tauro-obeticholic acid sodium | 2278141-79-8 | Tauro-obeticholate sodium is the active metabolite of obeticholic acid. |
|
V78711 | Tauro-β-muricholic acid-d4 sodium | Tauro-β-muricholic acid-d4 (sodium) is the deuterated form of Tauro-β-muricholic acid sodium. | |
|
V85883 | V023-9340 | 1048304-96-6 | |
|
V78572 | XJ02862-S2 | 3023355-55-4 | XJ02862-S2 has good FXR agonistic activity. |
|
V81777 | ZLY28 | 3004676-77-8 | ZLY28 is a first-in-class gut-restricted dual modulator of FXR and FABP1 with oral activity. |
|
V86290 | β-FXR antagonist 1 | 2295804-92-9 | |
|
V40096 | Glyco-Obeticholic acid | 863239-60-5 | Glyco-Obeticholic acid is an active metabolite of Obeticholic acid formed by a phase II metabolic reaction by conjugating with amino acid glycine. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
